BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi EK, Lee YS, Chern AKC, Jiampo P, Chutinet A, Hanafy DA, Trivedi P, Zhai D, Oh YS. Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran. Open Heart 2020;7:e001343. [PMID: 33184127 DOI: 10.1136/openhrt-2020-001343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Botto GL, Ameri P, De Caterina R. Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. J Clin Med 2021;10:2866. [PMID: 34203416 DOI: 10.3390/jcm10132866] [Reference Citation Analysis]
2 Salmasi S, Safari A, Kapanen A, Adelakun A, Kwan L, MacGillivray J, Andrade JG, Deyell MW, Loewen P. Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study. Res Social Adm Pharm 2022:S1551-7411(22)00180-2. [PMID: 35753963 DOI: 10.1016/j.sapharm.2022.06.002] [Reference Citation Analysis]
3 Lee YS, Oh YS, Choi EK, Chern AKC, Jiampo P, Chutinet A, Hanafy DA, Trivedi P, Zhai D. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study. Open Heart 2021;8:e001745. [PMID: 34857666 DOI: 10.1136/openhrt-2021-001745] [Reference Citation Analysis]